MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.rec.2014.02.019

Медицинская библиотека · Revista espanola de cardiologia (English ed.) · 2014

Initial experience of percutaneous treatment of mitral regurgitation with MitraClip® therapy in Spain.

Carrasco-Chinchilla Fernando, Arzamendi Dabit, Romero Miguel, Gimeno de Carlos Federico, Alonso-Briales Juan Horacio, Li Chi-Hion, Mesa Maria Dolores, Arnold Roman, Serrador Frutos Ana María, Pan Manuel, Roig Eulalia, Rodríguez-Bailón Isabel, de la Fuente Galán Luis, Hernández José María, Serra Antonio, Suárez de Lezo José

СтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION AND

OBJECTIVES

Symptomatic mitral regurgitation has an unfavorable prognosis unless treated by surgery. However, the European registry of valvular heart disease reports that 49% of patients with this condition do not undergo surgery. Percutaneous treatment of mitral regurgitation with MitraClip® has been proved a safe, efficient adjunct to medical treatment in patients with this profile. The objective of the present study is to describe initial experience of MitraClip® therapy in Spain.

METHODS

Retrospective observational study including all patients treated between November 2011 and July 2013 at the 4 Spanish hospitals recording the highest numbers of implantations.

RESULTS

A total of 62 patients (77.4% men) were treated, mainly for restrictive functional mitral regurgitation (85.4%) of grade III (37%) or grade IV (63%), mean (standard deviation) ejection fraction 36% (14%), and New York Heart Association functional class III (37%) or IV (63%). Device implantation was successful in 98% of the patients. At 1 year, 81.2% had mitral regurgitation ≤ 2 and 90.9% were in New York Heart Association functional class ≤ II. One periprocedural death occurred (sepsis at 20 days post-implantation) and another 3 patients died during follow-up (mean, 9.1 months). Two patients needed a second implantation due to partial dehiscence of the first device and 2 others underwent heart transplantation.

CONCLUSIONS

In Spain, MitraClip® therapy has principally been aimed at patients with functional mitral regurgitation, significant systolic ventricular dysfunction, and high surgical risk. It is considered a safe alternative treatment, which can reduce mitral regurgitation and improve functional capacity.

Для цитирования: Carrasco-Chinchilla Fernando, Arzamendi Dabit, Romero Miguel, Gimeno de Carlos Federico, Alonso-Briales Juan Horacio, Li Chi-Hion, Mesa Maria Dolores, Arnold Roman, Serrador Frutos Ana María, Pan Manuel, Roig Eulalia, Rodríguez-Bailón Isabel, de la Fuente Galán Luis, Hernández José María, Serra Antonio, Suárez de Lezo José. Initial experience of percutaneous treatment of mitral regurgitation with MitraClip® therapy in Spain.. Revista espanola de cardiologia (English ed.). 2014. DOI: 10.1016/j.rec.2014.02.019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.